Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
PLAINSBORO, N.J., Feb. 28, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conferences in March:
- At 9:00AM ET on Tuesday, March 14, 2017, Mr. Glenn Coleman, Chief Financial Officer and Corporate VP of International, will present at Barclays’ Global Healthcare Conference in Miami, FL. This presentation will be webcast.
- At 9:45AM ET on Tuesday, March 21, 2017, Mr. Coleman will present at Oppenheimer’s 27th Annual Healthcare Conference in New York City. This presentation will be webcast.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Angela Steinway (609) 936-2268 [email protected] Michael Beaulieu (609) 750-2827 [email protected]
